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Abstract A growing body of psychiatric research has
emerged, focusing on the role of endocannabinoid system
in psychiatric disorders. For example, the endocannabinoid
system, via cannabinoid CB (CB1 and CB2) receptors, is
able to control the function of many receptors, such as N-
methyl-D-aspartate (NMDA) receptors connected strictly
with psychosis or other schizophrenia-associated symp-
toms. The aim of the present research was to investigate the
impact of the CB1 receptor ligands on the symptoms typ-
ical for schizophrenia. We provoked psychosis-like effects
in mice by an acute administration of NMDA receptor
antagonist, MK-801 (0.1–0.6 mg/kg). An acute adminis-
tration of MK-801 induced psychotic symptoms, mani-
fested in the increase in locomotor activity (hyperactivity),
measured in actimeters, as well as the memory impairment,
assessed in the passive avoidance task. We revealed that an
acute injection of CB1 receptor agonist, oleamide
(5–20 mg/kg), had no influence on the short- and long-term
memory-related disturbances, as well as on the hyper-
locomotion in mice, provoking by an acute MK-801. In
turn, an amnestic effects or hyperactivity induced by an
acute MK-801 was attenuated by an acute administration of
AM 251 (0.25–3 mg/kg), a CB1 receptor antagonist. The
present findings confirm that endocannabinoid system is
able to modify a variety of schizophrenia-like responses,
including the cognitive disturbances and hyperlocomotion
in mice. Antipsychotic-like effects induced by CB1
receptor antagonist, obtained in our research, confirm the
potential effect of CB1 receptor blockade and could have
important therapeutic implications on clinical settings, in
the future.
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Introduction
Schizophrenia is a chronic, severe, mental disorder usually
characterized by abnormal social behavior. The main
symptoms of schizophrenia are often grouped into three
major diagnostic classes: positive, negative (or deficit)
symptoms, and cognitive disorders (Lewis and Liberman
2000).
It has been known that the function of different neuro-
transmitters systems, such as dopaminergic system, gluta-
matergic system, gamma-aminobutyric (GABA)-related
system, or/and endocannabinoid system, is altered in psy-
chosis (Broome et al. 2005; Carlsson 2004). The most
known hypothesis for schizophrenia is the glutamate (Glu)-
related hypothesis. Glu is the major excitatory neuro-
transmitter in the brain which has a leading role in neural
physiology, especially in mechanisms of synaptic plastic-
ity, such as the long-term potentiation (LTP) and long-term
depression underlying cellular basis of some phases of
memory and learning (Riedel et al. 2003; Shapiro 2001). It
has been revealed that glutamatergic transmission through
N-methyl-D-aspartate (NMDA)-type receptors is strictly
implicated in specific symptoms of schizophrenia, such as
psychosis. Furthermore, glutamatergic hypofunction,
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closely associated with NMDA receptors hypofunction, is
currently believed to provoke dopaminergic deregulation
observed in the brain of patients with schizophrenia (Har-
rison and Weinberger 2005; Javitt 2007) and underlie the
symptoms recognized as schizophrenia (Mohn et al. 1999;
Stone et al. 2007). Therefore, agonists of NMDA receptors
may have the potential to attenuate the symptoms of
schizophrenia, while antagonists of these receptors produce
psychotic symptoms and others schizophrenia-associated
symptoms (Abi-Saab et al. 1998).
A variety of pre-clinical and clinical studies have indi-
cated that endocannabinoid system participate in many
central pathways connected with psychosis-like state,
including glutamatergic transmission. In hippocampal slice
cultures (Khaspekov et al. 2004), and in cultured neurons
(Kim et al. 2006), it has been demonstrated that endo-
cannabinoid system through cannabinoid (CB: CB1 and
CB2) receptors is involved in the control of NMDA
receptors-related neuronal dysregulation, connected with
schizophrenia-like symptoms. This relationship has been
confirmed in behavioral studies (Liu et al. 2009; Marsicano
et al. 2003). For example, in animal models, it has been
demonstrated that CB1 receptor agonists often induced
cognitive impairments in rodents (Ferrari et al. 1999; Kruk-
Slomka and Biala 2016; Pamplona and Takahashi 2006),
whereas the antagonism of CB1 receptors generally
enhanced rodent performance in variety memory tasks
(Kruk-Slomka and Biala 2016; Lichtman 2000; Takahashi
et al. 2005; Terranova et al. 1996). Additionally, CB1
receptor agonists induced psychosis-like symptoms, and
CB1 receptor antagonists had antipsychotic properties
evaluated in animal models of schizophrenia (Almeida
et al. 2014; Levin et al. 2012; Roser and Haussleiter 2012).
Although the biochemical, molecular, and pharmacolog-
ical studies demonstrating functional interactions between
the glutamatergic and endocannabinoid system are available
(Rodrı´guez-Mun˜oz et al. 2012; Sa´nchez-Bla´zquez et al.
2014), many other interactions in the context of schizophre-
nia have not been yet examined. Therefore, the aim of pre-
sented studies was to evaluate the psychotic potential of CB1
receptor ligands and their influence on the psychosis-related
symptoms in mice. Our experiments have primarily focused
on the complex implication of the CB1 receptor subtype in the
schizophrenia-associated symptoms in mice, using a phar-
macological animal model of schizophrenia. We used a
potent agonist of CB1 receptor, oleamide, and a selective
CB1 receptor antagonist, AM 251. To provoke the symptoms
of schizophrenia in mice, we used NMDA receptor antago-
nist, MK-801. It has been known that an acute inhibition of
NMDA receptors, e.g., by MK-801, provokes schizophrenia-
like behavior in mice, both positive and negative symptoms
of this disorder, and shows phenomenological validity as a
model. This model is often used to predict the effect of many
compounds with potential antipsychotic properties (Large
2007). Concerning animal models, it is well assumed that an
acute administration of MK-801 in rodents induces psychotic
symptoms, manifested in the increase in locomotor activity
(hyperactivity) and memory impairment. Hyperlocomotion
in rodents has been correlated with the positive clinical
symptoms of schizophrenia (psychosis); in turn, memory-
related disturbances evaluated in animal tests have been
correlated to the cognitive deficits in humans (Arnt and
Skarsfeldt 1998; Bubeni9kova-Valesova et al. 2008; Micale
et al. 2013; Peleg-Raibstein et al. 2012). In our studies, a
different stages (acquisition, consolidation and retrieval) of
short- and long-term memory-related responses in mice were
measured in the commonly used animal model of memory—
the passive avoidance (PA) task—while locomotion was
measured in actimeters.
The results of this study will help increase knowledge on
the role of CB1 receptors, in the positive as well as cog-
nitive symptoms typical for schizophrenia, including
interactions between these receptors with other receptors
strictly associated with schizophrenia, e.g., NMDA recep-
tors. Perhaps, our results can be used to initiate new
research to clinical level and more effective strategies for
the control/attenuation of symptoms of schizophrenia and/
or other similar psychotic disorders.
Materials and Methods
Animals
The experiments were carried out on naive male Swiss
mice (Farm of Laboratory Animals, Warszawa, Poland)
weighing 20–30 g. The animals were maintained under
standard laboratory conditions (12-h light/dark cycle, room
temperature 21 ± 1 C) with free access to tap water and
laboratory feed (Agropol, Motycz, Poland) in their home
cages, and adapted to the laboratory conditions for at least
1 week. Each experimental group consisted of 8–12 ani-
mals. All behavioral experiments were performed between
8:00 and 15:00, and were conducted according to the
National Institute of Health Guidelines for the Care and
Use of Laboratory Animals and to the European Commu-
nity Council Directive for the Care and Use of laboratory
animals of 22 September 2010 (2010/63/EU) and approved
by the local ethics committee.
Drugs
The tested compounds were as follows:
Oleamide (5, 10, 20 mg/kg) (Tocris, USA)—CB1
receptor agonist.
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AM 251 (0.25, 0.5, 1, 3 mg/kg) (Tocris, USA)—CB1
receptor antagonist.
MK-801 (0.1, 0.3, 0.6 mg/kg) (Tocris, USA)—NMDA
receptor antagonist.
All CB compounds and MK-801 were suspended in a 1 %
solution of Tween 80 (Sigma, St. Louis, MO, USA) in saline
solution (0.9 % NACl) and administered intraperitoneally
(ip) at a volume of 10 ml/kg. Fresh drug solutions were
prepared on each day of experimentation. Control groups
received injections of saline with Tween 80 (vehicle) at the
same volume and by the same route of administration.
Experimental doses of drugs used and procedures were
selected on the basis of literature data (Akanmu et al. 2007;
Barzegar et al. 2015; Bialuk and Winnicka 2011; Bubenı´-
kova´-Valesova´ et al. 2010; Javadi-Paydar et al. 2012; Mur-
illo-Rodrı´guez et al. 2001; Nestler and Hyman 2010), our
previous experiments (Biala and Kruk 2008; Biala et al.
2009; Budzynska et al. 2009; Kruk-Slomka et al. 2015a, b;
Kruk-Slomka and Biala 2016), and preliminary studies.
Experimental Procedures
We used an animal model of schizophrenia. The used
procedure is commonly accepted (Bubenı´kova´-Valesova´
et al. 2010; Nestler and Hyman 2010) and is based on the
psychotic properties of NMDA receptor antagonist, e.g.,
MK-801. We provoked the schizophrenia-like behaviors
(cognitive disturbances and hyperlocomotion) in mice by
an acute administration of MK-801.
Next, we evaluated the influence of CB1 receptor
ligands, oleamide and AM 251, on the above schizophre-
nia-like effects in mice provoked by MK-801. Memory-
related responses in mice were measured in the PA task,
locomotion was measured in actimeters.
In the presented experiments, we used an independent
groups of mice for each kind of behavioral experiment
(separate group of mice for the assessment of memory-
related effects and separate group of mice for the assess-
ment of locomotor activity), for each drug and dose.
Memory-Related Responses
The apparatus of the PA consisted of two-compartment
acrylic box with a lighted compartment (10 9 13 9 15 cm)
and darkened compartment (25 9 20 9 15 cm). The light
chamber was illuminated by a fluorescent light (8 W) and
was connected to the dark chamber which was equipped with
an electric grid floor. Entrance of animals to the dark box was
punished by an electric foot shock (0.2 mA for 2 s).
On the first day of training (pretest), mice were placed
individually into the light compartment and allowed to
explore the light box. After 30 s, the guillotine door was
raised to allow the mice to enter the dark compartment.
When the mice entered to the dark compartment, the
guillotine door was closed and an electric foot shock
(0.2 mA) of 2 s duration was delivered immediately to the
animal via grid floor. The latency time for entering the dark
compartment was recorded (TL1). The mouse which did
not enter spontaneously into the dark box within 300 s was
excluded from further tests. In the subsequent trial (reten-
tion), the same mice were again placed individually in the
light compartment of the PA apparatus. After a 30-s
adaptation period in the light (safe) chamber, the door
between the compartments was raised and the time taken to
re-enter the dark compartment was recorded (TL2). No foot
shock was applied in this trial. Basically, in this kind of
procedure, when the mouse did not enter spontaneously
into the dark box within 300 s, the test was stopped.
Depending on the procedure used, PA test allows
examining different durations of memory (short-term and
long-term memory) according to the period between
training and test, as well as different stages of memory
(acquisition, consolidation, and retrieval) according to the
time of drug treatment.
When mice were tested 2 h after TL1, the short-term
memory was assessed, whereas longer time (24 h) allows
assess long-term memory processes. Drug administration
before the first trial (before pretest) should interfere with
the acquisition of information, and drug administration
immediately after the first trial (after pretest) should exert
an effect on the process of consolidation, while the
administration of tested compounds before the second trial
(before test) should interfere with the retrieval of memory
information (Allami et al. 2011; Javadi-Paydar et al. 2012;
Kruk-Slomka et al. 2015a; Kruk-Slomka and Biala 2016).
Locomotion
Locomotion of mice was recorded individually in round
actimeter cages (Multiserv, Lublin, Poland; 32 cm in
diameter, two light beams) kept in a sound-attenuated
experimental room. Two photocell beams, located across
the axis, automatically measured animal’s movements. The
horizontal locomotor activity, i.e., the number of photocell
beam breaks, was automatically measured with a 20-min
interval for 200 min (Mohn et al. 1999; Zhou et al. 2012).
Treatment
For Memory-Related Responses
The first step of experiment was designed to estimate the
influence of MK-801 (0.1, 0.3 and 0.6 mg/kg; ip) on the
different stages of short- as well as long-term memory in
mice, using the PA test.
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For the acquisition of memory, MK-801 or vehicle, for
the control group, was administered 30 min before the first
trial, and mice were re-tested after 2 h (short-term mem-
ory) or after 24 h (long-term memory). For the consoli-
dation of memory, MK-801 or vehicle, for the control
group, was injected immediately after the first trial, and
mice were re-tested after 2 h or after 24 h. Finally, for the
retrieval of memory, MK-801 or vehicle, for the control
group, was injected 30 min before retrieval and that
retrieval was carried out 2 or 24 h after the first trial
(Table 1).
Based on this pilot experiment, we have chosen the most
effective doses of MK-801 in the PA test in mice for the
next experiments with CB1 receptor ligands. After that,
based on the available literature data (Barzegar et al. 2015)
and primarily on the results obtained from our previous
experiments (Kruk-Slomka and Biala 2016), in which we
determined the effects of an acute injection of different
doses of oleamide (5–20 mg/kg), a CB1 receptor agonist
and different doses of AM 251 (0.25–3 mg/kg), a CB1
receptor antagonist, on the short-term or long-term memory
stages in the inhibitory avoidance (IA) task in mice, we
have chosen the non-effective dose of oleamide (5 mg/kg)
and AM 251 (0.25 mg/kg) for the next experiment with
MK-801. We evaluated the influence of oleamide and AM
251 on the memory-related responses induced by MK-801
in the PA task.
Non-effective oleamide (5 mg/kg; ip) (Kruk-Slomka
and Biala 2016) or vehicle was administered acutely
15 min before an acute injection of MK-801 (0.3 mg/kg,
ip) or vehicle. Similarly, non-effective dose of AM 251
(0.25 mg/kg, ip) (Kruk-Slomka and Biala 2016) or vehicle
were administered acutely 15 min before an acute injection
of MK-801 (0.3 mg/kg, ip) or vehicle. The mice were then
tested for acquisition, consolidation, and retrieval of short-
and long-term memory in the same scheme described
above and presented in the Table 2.
For Psychotic-Like Symptoms
Horizontal locomotor activity was measured immediately
after an acute injection of MK-801 (0.1; 0.3; 0.6 mg/kg;
ip), oleamide (5; 10; 20 mg/kg, ip), AM 251 (0.25; 0.5; 1
and 3 mg/kg, ip), or vehicle for the control group. Next, we
evaluated the impact of an acute administration of olea-
mide (5–20 mg/kg, ip) or AM 251 (0.25–3 mg/kg, ip) on
the hyperlocomotion of mice provoked by an acute MK-
801 (0.1–0.6 mg/kg, ip). For this purpose, oleamide, AM
251, or vehicle were administered 15 min before injection
of MK-801 or vehicle. The mice were then tested imme-
diately after the last injection (Table 3).
Statistical Analysis
The statistical analysis was performed using one-way
analysis of variance (ANOVA) or two-way ANOVA—for
the factors of pretreatment (oleamide or AM 251), treat-
ment (MK 801), and pretreatment/treatment interactions
for the memory-related responses or for the factors of time,
drugs, and time/drugs interactions for the psychotic-like
symptoms.
Post hoc comparison of means was carried out with the
Tukey’s test (for one-way ANOVA) or with the Bonfer-
roni’s test (for two-way ANOVA) for multiple
Table 1 The scheme of MK-
801 or vehicle administration
during the assessment of short-
and long-term memory
acquisition (A), consolidation
(B), or retrieval (C) in the PA
test
A. Acquisition of memory
Drug administration Interval TL1 Interval TL2
Short-term memory MK-801 (0.1–0.6 mg/kg) or vehicle 30 min ? 2 h ?
Long-term memory MK-801 (0.1–0.6 mg/kg) or vehicle 30 min ? 24 h ?
B. Consolidation of memory
TL1 Interval Dug administration Interval TL2
Short-term memory ? 0 min MK-801 (0.1–0.6 mg/kg) or vehicle 2 h ?
Long-term memory ? 0 min MK-801 (0.1–0.6 mg/kg) or vehicle 24 h ?
C. Retrieval of memory
TL1 Interval Drug administration Interval TL2
Short-term memory ? 2 h MK-801 (0.1–0.6 mg/kg) or vehicle 30 min ?
Long-term memory ? 24 h MK-801 (0.1–0.6 mg/kg) or vehicle 30 min ?
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comparisons, when appropriate. The data were considered
statistically significant at confidence limit of p\ 0.05.
ANOVA analysis with Tukey’s or Bonferroni’s post-tests
was performed using GraphPad Prism version 5.00 for
Windows, GraphPad Software, San Diego California USA,
www.graphpad.com.
For the memory-related responses, the changes in PA
performance were expressed as the difference between
retention and training latencies and were taken as a latency
index (LI). LI was calculated for each animal and reports as
the ratio: LI = TL2-TL1/TL1, where TL1 is the time
taken to enter the dark compartment during the training and
TL2 is the time taken to re-enter the dark compartment
during the retention (Chimakurthy and Talasila 2010).
For the psychotic-like symptoms, the horizontal loco-
motor activity, i.e., the number of photocell beam breaks,
was measured.
Results
First, we induced the memory disturbances characteristic
for schizophrenia (negative symptoms), by the acute
administration of MK-801, and evaluated the influence of
Table 3 The scheme of drugs (MK-801, oleamide, AM 251) or vehicle administration (A) and drugs co-administration (B) during the
assessment of locomotor activity of mice
A. Locomotor activity
Drug administration Interval Measurement of locomotor activity for
200 min




Drugs administration Interval Drug administration Interval Measurement of locomotor activity
for 200 min
oleamide (5 mg/kg) or AM 251 (0.25 and 0.5 mg/
kg) or vehicle
15 min MK-801 (0.3 and 0.6 mg/kg)
or vehicle
0 min ?
Table 2 The scheme of oleamide (5 mg/kg) or AM 251 (0.25 mg/kg) and MK-801 (0.3 mg/kg) co-administration during the assessment of
short- and long-term memory acquisition (A), consolidation (B), or retrieval (C) in the PA test
A. Acquisition of memory
Drug administration Interval Drug administration Interval TL1 Interval TL2
Short-term
memory
oleamide (5 mg/kg) or AM (0.25 mg/kg) or
vehicle
15 min MK-801 (0.3 mg/kg) or
vehicle
15 min ? 2 h ?
Long-term
memory
oleamide (5 mg/kg) or AM (0.25 mg/kg) or
vehicle
15 min MK-801 (0.3 mg/kg) or
vehicle
15 min ? 24 h ?
B. Consolidation of memory
TL1 Interval Drug administration Interval Drug administration Interval TL2
Short-term
memory
? 0 min oleamide (5 mg/kg) or AM (0.25 mg/kg) or
vehicle





? 0 min oleamide (5 mg/kg) or AM (0.25 mg/kg) or
vehicle
15 min MK-801 (0.3 mg/kg) or
vehicle
24 h ?
C. Retrieval of memory
TL1 Interval Drug co-administration Interval Drug administration Interval TL2
Short-term
memory
? 2 h oleamide (5 mg/kg) or AM (0.25 mg/kg) or
vehicle





? 24 h oleamide (5 mg/kg) or AM (0.25 mg/kg) or
vehicle
15 min MK-801 (0.3 mg/kg) or
vehicle
15 min ?
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CB1 receptor ligands on these memory impairment pro-
voked by MK-801.
Memory-Related Disturbances in the PA Test
in Mice Provoked by an Acute Administration
of MK-801
Acquisition of Memory
One-way ANOVA revealed that administration of acute ip
doses of MK-801 (0.1; 0.3 and 0.6 mg/kg) had a statisti-
cally significant effect on LI values for short-term memory
acquisition [F(3.31) = 6.283; p = 0.0021], as well as for
long-term memory acquisition [F(3.32) = 8.619;
p = 0.0003]. Indeed, the post hoc Tukey’s test confirmed
that the treatment with MK-801 (0.3 and 0.6 mg/kg) sig-
nificantly decreased LI values in mice compared to those in
the vehicle-treated control group (p\ 0.01—for short-term
memory acquisition (Fig. 1Aa), and p\ 0.01; p\ 0.001—
for long-term memory acquisition, for the dose of 0.3 and
0.6 mg/kg, respectively) (Fig. 1Ab), indicating that MK-
801, at these used doses, impaired both the short- and long-
term acquisition of memory and learning.
Consolidation of Memory
One-way ANOVA indicated that administration of acute ip
doses of MK-801 (0.1; 0.3 and 0.6 mg/kg) had a statisti-
cally significant effect on LI values for short-term memory
consolidation [F(3.32) = 5.585; p = 0.0038], as well as
for long-term memory consolidation [F(3.29) = 6.436;
p = 0.0021]. Indeed, treatment with MK-801 significantly
decreased LI values in mice compared to those in the
vehicle-treated control group for short-term memory con-
solidation (p\ 0.05 for dose of 0.1 mg/kg; p\ 0.01 for
dose of 0.3 mg/kg; Tukey’s test) (Fig. 1Ba), and for long-
term memory consolidation (p\ 0.05 for dose of 0.3 mg/
kg and 0.6 mg/kg; p\ 0.01 for dose of 0.1 mg/kg; Tukey’s
test) (Fig. 1Bb), indicating that MK-801, at these used
doses, impaired the short- and/or long-term consolidation
of memory and learning.
Retrieval of Memory
One-way ANOVA indicated that administration of acute ip
doses of MK-801 (0.1; 0.3 and 0.6 mg/kg) had a statisti-
cally significant effect on LI values for short-term memory
retrieval [F(3.28) = 3.777; p = 0.0231], as well as for
long-term memory consolidation [F(3.32) = 7.284;
p = 0.0009]. Indeed, treatment with MK-801 significantly
decreased LI values in mice compared to those in the
vehicle-treated control group for short-term memory
retrieval (p\ 0.05 for dose of 0.1 and 0.3 mg/kg; Tukey’s
test) (Fig. 1Ca), and for long-term memory retrieval
(p\ 0.05 for dose of 0.6 mg/kg; p\ 0.01 for dose of 0.1
and 0.3 mg/kg; Tukey’s test) (Fig. 1Cb), indicating that
MK-801, at these used doses, impaired the short- and/or
long-term retrieval of memory and learning.
In our previously published experiments, we revealed
that an acute injection of oleamide (10 and 20 mg/kg), a
CB1 receptor agonist, diminished the short-term as well as
long-term acquisition, consolidation/retention, and/or
retrieval of memory and learning in the IA task. In turn, an
acute injection of AM 251 (1 and 3 mg/kg), a CB1 receptor
antagonist, improved stages of the short-term or long-term
memory, mentioned above. This memory impairment
induced by effective dose of oleamide (20 mg/kg) was
reversed by a non-effective dose of CB1 receptor antago-
nist, AM 251 (0.25 mg/kg) in mice using the IA test,
confirming that the CB1 receptor-related mechanism is one
of the possible mechanisms responsible for memory and
learning responses (Kruk-Slomka and Biala 2016).
Therefore, based on the results obtained from these cited
experiments (Kruk-Slomka and Biala 2016), the non-ef-
fective dose of oleamide (5 mg/kg) and non-effective dose
of AM 251 (0.25 mg/kg) were then chosen for the next
behavioral experiment evaluating the influence of these
CB1 receptor ligands on the above-described memory
impairment, provoked by an acute injection of MK-801
(0.3 mg/kg), using the PA test in mice.
The Influence of the Administration of Oleamide
on the Memory Impairment Provoked by an Acute
Administration of MK-801 in the PA Test in Mice
Acquisition of Memory
For short-term memory acquisition, two-way ANOVA anal-
yses revealed that there was no statistically significant effect
caused by oleamide (5 mg/kg) pretreatment [F(1.28) = 0.18;
p = 0.6766], but there was a statistically significant effect
caused by MK-801 (0.3 mg/kg) treatment [F(1.28) = 11.40;
p = 0.0022] and interactions [F(1.28) = 5.02; p = 0.0331].
The post hoc Bonferroni’s test confirmed that MK-801 at the
dose of 0.3 mg/kg significantly decreased LI values in mice in
the PA test in comparison to the vehicle/vehicle-treated mice,
pointing to the amnestic effect of this drug (p\ 0.01). How-
ever, oleamide (5 mg/kg) had no influence on this amnestic
effect of MK-801 (0.3 mg/kg) (Fig. 2Aa).
For long-term memory acquisition, two-way ANOVA
analyses revealed that there was no statistically significant
effect caused by oleamide (5 mg/kg) pretreatment
[F(1.32) = 0.46; p = 0.5003] as well as by interactions
between oleamide (5 mg/kg) pretreatment and MK-801
(0.3 mg/kg) treatment [F(1.32) = 0.68; p = 0.4170], but
there was a statistically significant effect caused by MK-
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b. Long-term memory retrieval
**
***
Fig. 1 Effects of an acute MK-801 or saline administration on the
latency index (LI) during the short-term or long-term acquisition trial
(A), consolidation trial (B), and retrieval trial (C), using the PA test in
mice. MK-801 (0.1; 0.3 and 0.6 mg/kg; ip) or vehicle was injected
30 min before the first trial (A) or immediately after first trial (B), and
mice were re-tested 2 h [for short-term memory (a)] or 24 h [for long-
term memory (b)] later. In the case of retrieval of memory (C),
oleamide, MK-801 (0.1, 0.3 and 0.6 mg/kg; ip) or vehicle was
administered 2 h (a) or 24 h (b) after the first trial,and mice were re-
tested 30 min after the last injection; n = 8–12; the mean ± SEM;
*p\ 0.05; **p\ 0.01; ***p\ 0.001 vs. vehicle-treated control
group; Tukey’s test
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801 (0.3 mg/kg) treatment [F(1.32) = 9.97; p = 0.0035].
The post hoc Bonferroni’s test revealed that MK-801 at the
dose of 0.3 mg/kg significantly decreased LI values in mice
in the PA test in comparison to the vehicle/vehicle-treated
mice, confirming the amnestic effect of this drug
(p\ 0.05). Oleamide (5 mg/kg) had no influence on this
amnestic effect of MK-801 (0.3 mg/kg) (Fig. 2Ab).
Consolidation of Memory
For short-term memory consolidation, two-way ANOVA
analyses revealed that there was no statistically significant
effect caused by oleamide (5 mg/kg) pretreatment
[F(1.28) = 0.01; p = 0.9200] as well as by interactions
between oleamide (5 mg/kg) pretreatment and MK-801
(0.3 mg/kg) treatment [F(1.28) = 2.20; p = 0.1496], but
there was a statistically significant effect caused by MK-
801 (0.3 mg/kg) treatment [F(1.28) = 5.11; p = 0.0318].
The post hoc Bonferroni’s test revealed that MK-801 at the
dose of 0.3 mg/kg significantly decreased LI values in mice
in the PA test in comparison to the vehicle/vehicle-treated
mice, confirming the amnestic effect of this drug
(p\ 0.05). Oleamide (5 mg/kg) had no influence on this
amnestic effect of MK-801 (0.3 mg/kg) (Fig. 2Ba).
For long-term memory consolidation, two-way ANOVA
analyses revealed that there was no statistically significant
effect caused by oleamide (5 mg/kg) pretreatment
[F(1.25) = 0.20; p = 0.6585], MK-801 (0.3 mg/kg) treat-
ment [F(1.25) = 2.49; p = 0.1270], as well as by inter-
actions between oleamide (5 mg/kg) pretreatment and MK-
801 (0.3 mg/kg) treatment [F(1.25) = 0.84; p = 0.3694].
Oleamide (5 mg/kg) had no influence on this amnestic
effect of MK-801 (0.3 mg/kg) (Fig. 2Bb).
Retrieval of Memory
For short-term memory retrieval, two-way ANOVA anal-
yses revealed that there was no statistically significant
effect caused by oleamide (5 mg/kg) pretreatment
[F(1.26) = 2.59; p = 0.1196], as well as by interactions
between oleamide (5 mg/kg) pretreatment and MK-801
(0.3 mg/kg) treatment [F(1.26) = 1.23; p = 0.2774], but
there was a statistically significant effect caused by MK-
801 (0.3 mg/kg) treatment [F(1.26) = 11.17; p = 0.0025].
The post hoc Bonferroni’s test confirmed that MK-801 at
the dose of 0.3 mg/kg significantly decreased LI values in
mice in the PA test in comparison to the vehicle/vehicle-
treated mice, pointing to the amnestic effect of this drug
(p\ 0.01), and that oleamide (5 mg/kg) had no influence
on this amnestic effect of MK-801 (0.3 mg/kg) (Fig. 2Ca).
For long-term memory retrieval, two-way ANOVA
analyses revealed that there was no statistically significant
effect caused by oleamide (5 mg/kg) pretreatment
[F(1.24) = 1.47; p = 0.2377], as well as by interactions
between oleamide (5 mg/kg) pretreatment and MK-801
(0.3 mg/kg) treatment [F(1.24) = 1.10; p = 0.3057], but
there was a statistically significant effect caused by MK-
801 (0.3 mg/kg) treatment [F(1.24) = 25.02; p\ 0.0001].
The post hoc Bonferroni’s test confirmed that MK-801 at
the dose of 0.3 mg/kg significantly decreased LI values in
mice in the PA test in comparison to the vehicle/vehicle-
treated mice, pointing to the amnestic effect of this drug
(p\ 0.01), and that oleamide (5 mg/kg) had no influence
on this amnestic effect of MK-801 (0.3 mg/kg) (Fig. 2Ca).
The Influence of the Administration of AM 251
on the Memory Impairment Provoked by MK-801
in the PA Test in Mice
Acquisition of Memory
For short-term memory acquisition, two-way ANOVA
analyses revealed that there was no statistically significant
effect caused by MK-801 (0.3 mg/kg) treatment
[F(1.28) = 0.29; p = 0.5922], but there was a statistically
significant effect caused by AM 251 (0.25 mg/kg) pre-
treatment [F(1.28) = 7.37; p = 0.0112] and interactions
[F(1.28) = 11.52; p = 0.0021]. The post hoc Bonferroni’s
test revealed that MK-801 at the dose of 0.3 mg/kg sig-
nificantly decreased LI values in mice in the PA test in
comparison to the vehicle/vehicle-treated mice, confirming
an amnestic effect of this drug (p\ 0.05). This amnestic
effect of MK-801 (0.3 mg/kg) was reversed by AM 251
(0.25 mg/kg) (p\ 0.01 vs. vehicle/MK-801(0.3 mg/kg)-
treated mice) (Fig. 3Aa).
For long-term memory acquisition, two-way ANOVA
analyses revealed that there was a statistically significant
effect of interactions between MK-801 (0.3 mg/kg) treat-
ment and AM 251 (0.25 mg/kg) pretreatment
[F(1.30) = 7.90; p = 0.0086], but there was no statisti-
cally significant effect of MK-801 (0.3 mg/kg) treatment
[F(1.30) = 0.51; p = 0.4819], as well as AM 251
bFig. 2 Influence of oleamide on the memory-related responses,
expressed as latency index (LI) during the short-term (a) or long-term
(b) acquisition (A), consolidation (B), and retrieval (C) trial, induced
by an acute administration of MK-801, using the PA test in mice.
Non-effective dose of oleamide (5 mg/kg, ip) or vehicle was
administered 15 min prior to vehicle or effective (0.3 mg/kg, ip)
MK-801 injection. All drugs were administered 15 min before the
first trial (A) or immediately after the first trial (B), and mice were re-
tested 2 h (for short-term memory) or 24 h (for long-term memory)
later. In the case of retrieval of memory (C), all drugs were
administered 2 h (a) or 24 h (b) after the first trial, and mice were re-
tested 15 min after the last injection; n = 8–12; the mean ± SEM;
^p\ 0.05; ^^p\ 0.01 vs. vehicle/vehicle-treated group; two-way
ANOVA/Bonferroni test
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(0.25 mg/kg) pretreatment [F(1.30) = 2.59; p = 0.1178].
The post hoc Bonferroni’s test indicated that MK-801 at
the dose of 0.3 mg/kg significantly decreased LI values in
mice in the PA test in comparison to the vehicle/vehicle-
treated mice, confirming an amnestic effect of this drug
(p\ 0.05), and this memory impairment caused by MK-
801 (0.3 mg/kg) was attenuated by AM 251 (0.25 mg/kg)
(p\ 0.05 vs. vehicle/MK-801 (0.3 mg/kg)-treated mice)
(Fig. 3Ab).
Consolidation of Memory
For short-term memory consolidation, two-way ANOVA
analyses revealed that there was no statistically significant
effect caused by MK-801 (0.3 mg/kg) treatment
[F(1.29) = 0.78; p = 0.3858], but there was a statistically
significant effect caused by AM 251 (0.25 mg/kg) pre-
treatment [F(1.29) = 10.74; p = 0.0027] and interactions
[F(1.29) = 21.45; p\ 0.0001]. The post hoc Bonferroni’s
test revealed that MK-801 at the dose of 0.3 mg/kg sig-
nificantly decreased LI values in mice in the PA test in
comparison to the vehicle/vehicle-treated mice, confirming
an amnestic effect of this drug (p\ 0.05). This amnestic
effect of MK-801 (0.3 mg/kg) was reversed by AM 251
(0.25 mg/kg) (p\ 0.001 vs. vehicle/MK-801(0.3 mg/kg)-
treated mice) (Fig. 3Ba).
For long-term memory consolidation, two-way ANOVA
analyses revealed that there was no statistically significant
effect caused by MK-801 (0.3 mg/kg) treatment
[F(1.25) = 0.06; p = 0.802], not quite statistically signif-
icant effect caused by AM 251 (0.25 mg/kg) pretreatment
[F(1.25) = 3.39; p = 0.0774], and there was a statistically
significant effect caused by interactions between AM 251
(0.25 mg/kg) pretreatment and MK-801 (0.3 mg/kg)
treatment [F(1.25) = 10.33; p = 0.0036]. The post hoc
Bonferroni’s test revealed that MK-801 at the dose of
0.3 mg/kg significantly decreased LI values in mice in the
PA test in comparison to the vehicle/vehicle-treated mice,
confirming an amnestic effect of this drug (p\ 0.05), and
additionally, this amnestic effect of MK-801 (0.3 mg/kg)
was reversed by AM 251 (0.25 mg/kg) (p\ 0.05 vs.
vehicle/MK-801(0.3 mg/kg)-treated mice) (Fig. 3Bb).
Retrieval of Memory
For short-term memory retrieval, two-way ANOVA anal-
yses revealed that there was no statistically significant
effect caused by MK-801 (0.3 mg/kg) treatment
[F(1.28) = 0.00; p = 0.9671], not quite statistically sig-
nificant effect caused by AM 251 (0.25 mg/kg) pretreat-
ment [F(1.28) = 2.92; p = 0.0985], and there was a
statistically significant effect caused by interactions
between AM 251 (0.25 mg/kg) pretreatment and MK-801
(0.3 mg/kg) treatment [F(1.28) = 6.74; p = 0.0148]. The
post hoc Bonferroni’s test revealed that MK-801 at the
dose of 0.3 mg/kg significantly decreased LI values in mice
in the PA test in comparison to the vehicle/vehicle-treated
mice, confirming an amnestic effect of this drug
(p\ 0.05), and additionally, this amnestic effect of MK-
801 (0.3 mg/kg) was attenuated by AM 251 (0.25 mg/kg)
(p\ 0.05 vs. vehicle/MK-801(0.3 mg/kg)-treated mice)
(Fig. 3Ca).
For long-term memory retrieval, two-way ANOVA
analyses revealed that there was no statistically significant
effect caused by MK-801 (0.3 mg/kg) treatment
[F(1.27) = 0.35; p = 0.5584], not quite statistically sig-
nificant effect caused by AM 251 (0.25 mg/kg) pretreat-
ment [F(1.27) = 3.34; p = 0.0788], and there was a
statistically significant effect caused by interactions
between AM 251 (0.25 mg/kg) pretreatment and MK-801
(0.3 mg/kg) treatment [F(1.27) = 7.60; p = 0.0103]. The
post hoc Bonferroni’s test revealed that MK-801 at the
dose of 0.3 mg/kg significantly decreased LI values in mice
in the PA test in comparison to the vehicle/vehicle-treated
mice, confirming an amnestic effect of this drug
(p\ 0.05). This memory impairment provoked by MK-
801 (0.3 mg/kg) was attenuated by AM 251 (0.25 mg/kg)
(p\ 0.05 vs. vehicle/MK-801(0.3 mg/kg)-treated mice)
(Fig. 3Cb).
In the next step, we induced the hyperlocomotion
characteristic for schizophrenia (positive symptoms) pro-
voked by the acute administration of MK-801 and evalu-
ated the influence of CB1 receptor ligands on this MK-801-
related hyperactivity.
Hyperactivity of Mice Measured in Actimeters
Provoked by an Acute Administration of MK-801
Two-way ANOVA analyses revealed that there was statis-
tically significant effect caused by time [F(10.264) = 41.83;
p\ 0.0001], and MK-801 (0.1; 0.3 and 0.6 mg/kg) treat-
ment [F(3.264) = 91.64; p\ 0.0001], as well as by inter-
actions between time and MK-801 treatment [F(30.264) =
bFig. 3 Influence of AM 251 on the memory-related responses,
expressed as latency index (LI) during the short-term (a) or long-term
(b) acquisition (A), consolidation (B), and retrieval (C) trial, induced
by an acute administration of MK-801, using the PA test in mice.
Non-effective dose of AM 251 (0.25 mg/kg, ip) or vehicle was
administered 15 min prior to vehicle or effective (0.3 mg/kg, ip) MK-
801 injection. All drugs were administered 15 min before the first trial
(A) or immediately after the first trial (B), and mice were re-tested 2 h
(for short-term memory) or 24 h (for long-term memory) later. In the
case of retrieval of memory (C), all drugs were administered 2 h
(a) or 24 h (b) after the first trial, and mice were re-tested 15 min after
the last injection; n = 8–12; the mean ± SEM; ^p\ 0.05 vs. vehicle/
vehicle-treated group; *p\ 0.05; ***p\ 0.01 vs. vehicle/MK-801
(0.3 mg/kg)-treated group; Bonferroni’s test
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2.78; p\ 0.0001]. The Bonferroni’s test revealed that an
acute injection of MK-801 at the dose of 0.3 mg/kg signifi-
cantly increased locomotor activity of mice between 60 and
200 min of experiment as compared with the vehicle-ad-
ministered control group (for 60 min of experiments
p\ 0.01; for 80 and 100 min p\ 0.001; for 120–160 min
p\ 0.01; for 180 and 200 min p\ 0.05). Similarly, the
Bonferroni’s test revealed that an acute injection of MK-801
at the dose of 0.6 mg/kg significantly increased locomotor
activity of mice between 80 and 200 min of experiment as
compared with the vehicle-administered control group (for
80 min of experiments p\ 0.01; for 100–200 min
p\ 0.001). MK-801 at the dose of 0.1 mg/kg had no influ-
ence on the locomotor activity of mice in comparison to the
vehicle-treated control group (Fig. 4A).
The Influence of CB1 Receptor Agonist, Oleamide,
on the Locomotor Activity of Mice
Two-way ANOVA analyses revealed that there was sta-
tistically significant effect caused by time [F(10.264) =
22.85; p\ 0.0001], and oleamide (5; 10 and 20 mg/kg)
treatment [F(3.264) = 30.26; p\ 0.0001], but there was
no statistically significant effect caused by interactions
between time and oleamide treatment [F(30.264) = 0.95;
p = 0.5512]. The Bonferroni’s test revealed that an acute
injection of oleamide at the dose of 10 mg/kg significantly
decreased locomotion in mice between 160 and 200 min of
experiments in comparison to the vehicle-treated control
group (p\ 0.05). Similarly, the Bonferroni’s test revealed
that an acute injection of oleamide at the dose of 20 mg/kg
significantly decreased locomotor activity of mice between
120 and 200 min of experiment as compared with the
vehicle-treated control group (for 120 and 140 min of
experiments p\ 0.01; for 160–200 min p\ 0.001).
Oleamide at the dose of 5 mg/kg had no influence on the
locomotor activity of mice in comparison to the vehicle-
treated control group (Fig. 4B).
The Influence of CB1 Receptor Antagonist, AM 251,
on the Locomotor Activity of Mice
Two-way ANOVA analyses revealed that there was statis-
tically significant effect caused by time [F(10.330) = 34.81;
p\ 0.0001], and AM 251 (0.25; 0.5; 1 and 3 mg/kg) treat-
ment [F(4.330) = 24.32; p\ 0.0001], but there was no
statistically significant effect caused by interactions between
time and AM 251 treatment [F(40.330) = 1.10; p =
0.3203]. The Bonferroni’s test revealed that an acute injec-
tion of AM 251 at the dose of 1 mg/kg significantly
decreased locomotion in mice between 140 and 200 min of
experiments in comparison to the vehicle-treated control
group (for 140 and 160 min of experiments p\ 0.05; 180
and 200 min p\ 0.01). Similarly, the Bonferroni’s test
revealed that an acute injection of AM 251 at the dose of
3 mg/kg significantly decreased locomotor activity of mice
between 120 and 200 min of experiment as compared with
the vehicle-administered control group (for 120 and 140 min
of experiments p\ 0.01; for 160–200 min p\ 0.001). AM
251 at the doses of 0.25 and 0.5 mg/kg had no influence on
the locomotor activity of mice in comparison to the vehicle-
treated control group (Fig. 4C).
Based on the results obtained from these two experi-
ments in the actimeters, the effective doses of MK-801 (0.3
and 0.6 mg/kg) and non-effective doses of oleamide (5 mg/
kg) and AM 251 (0.25 and 0.5 mg/kg) were then chosen for
the next behavioral experiment evaluating the involvement
of CB1 receptors in the MK-801-induced hyperactivity.
The Influence of the Administration of Oleamide
on the Hyperactivity of Mice Provoked by an Acute
Administration of MK-801
Two-way ANOVA analyses revealed that there was statis-
tically significant effect caused by time [F(10.264) = 22.11;
p\ 0.0001], and drugs (MK-801 (0.3 mg/kg) and/or olea-
mide (5 mg/kg) treatment [F(3.264) = 47.13; p\ 0.0001],
but there was no statistically significant effect caused by
interactions between time and drugs treatment [F(30.264) =
0.89; p = 0.6358]. The post hoc Bonferroni’s test confirmed
that an acute injection of MK-801 at the dose of 0.3 mg/kg
significantly increased locomotor activity of mice between
80 and 200 min of experiment as compared with the vehicle/
vehicle-injected control group (for 80 min of experiments p
\ 0.01; for 100 min p\ 0.001; for 120–160 min p\ 0.01;
for 180 and 200 min p\ 0.05). Oleamide (5 mg/kg) had no
influence on MK-801 (0.3 mg/kg)-induced hyperactivity
(Fig. 5A). Indeed, two-way ANOVA analyses revealed that
there was statistically significant effect caused by time
[F(10.264) = 39.46; p \ 0.0001], and drugs (MK-801
(0.6 mg/kg) and/or oleamide (5 mg/kg) treatment
[F(3.264) = 72.39; p\ 0.0001], as well as by interactions
between time and drugs treatment [F(30.264) = 2.06;
p = 0.0014]. The post hoc Bonferroni’s test revealed that
MK-801 at the dose of 0.6 mg/kg significantly increased
locomotor activity of mice in actimeters between 80 and
200 min of experiments (for 80 min of experiments
p\ 0.05; for 100 min p\ 0.01; for 120–200 min
p\ 0.001), in comparison to the vehicle/vehicle-treated
mice. Oleamide (5 mg/kg) had no influence on MK-801
(0.6 mg/kg)-induced hyperactivity (Fig. 5B).
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Fig. 4 Effects of an acute MK-
801 (A), oleamide (B), AM 251
(C) or vehicle administration on
the locomotor activity in mice.
MK-801 (0.1; 0.3 and 0.6 mg/
kg; ip), oleamide (5; 10 and
20 mg/kg; ip), AM 251 (0.25;
0.5; 1 and 3 mg/kg; ip), or
vehicle were immediately
before the test; n = 8–12; the
mean ± SEM; *p\ 0.05;
**p\ 0.01; ***p\ 0.001 vs.
vehicle-treated control group;
Bonferroni’s test
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The Influence of the Administration of AM 251
on the Hyperactivity of Mice Provoked by an Acute
Administration of MK-801
1. Two-way ANOVA analyses revealed that there was
statistically significant effect caused by time
[F(10.264) = 32.61; p\ 0.0001], and drugs (MK-801
(0.3 mg/kg) and/or AM 251 (0.25 mg/kg) treatment
[F(3.264) = 56.55; p\ 0.0001], but there was no statisti-
cally significant effect caused by interactions between time
and drugs treatment [F(30.264) = 1.12; p = 0.3065]. The
post hoc Bonferroni’s test confirmed that an acute injection
of MK-801 at the dose of 0.3 mg/kg significantly increased
locomotor activity of mice between 80 and 200 min of
experiment in comparison to the vehicle/vehicle-treated
mice (for 80 min of experiments p\ 0.01; for 100 min
p\ 0.001, for 120–160 min p\ 0.01, for 180 and 200 min
p\ 0.05). Moreover, this hyperactivity provoked by MK-
801 (0.3 mg/kg) was attenuated by AM 251 (0.25 mg/kg)
between 120 and 200 min of experiment (for 120–160 min
of experiment p\ 0.05, for 180–200 min p\ 0.01 vs.
vehicle/MK-801 (0.3 mg/kg)-treated mice) (Fig. 6Aa). In
turn, for the experiments dealing with MK-801 at the dose
of 0.6 mg/kg, two-way ANOVA analyses indicated that
there was statistically significant effect caused by time
[F(10.264) = 55.82; p\ 0.0001], and drugs (MK-801
(0.6 mg/kg) and/or AM 251 (0.25 mg/kg) treatment
[F(3.264) = 77.11; p\ 0.0001], as well as by interactions
between time and drugs treatment [F(30.264) = 2.79;
p\ 0.0001]. The Bonferroni’s test confirmed that an acute
injection of MK-801 at the dose of 0.6 mg/kg significantly
increased locomotor activity of mice between 80 and
200 min of experiment as compared with the control
vehicle/vehicle-treated mice, (for 80 min of experiments
p\ 0.01; for 100–200 min p\ 0.001). AM 251 (0.25 mg/
kg) had no influence on MK-801 (0.6 mg/kg)-induced
hyperactivity (Fig. 6Ba).
2. Two-way ANOVA analyses revealed that there
was statistically significant effect caused by time
[F(10.264) = 40.66; p\ 0.0001], and drugs (MK-801
(0.3 mg/kg) and/or AM 251 (0.5 mg/kg) treatment
[F(3.264) = 64.35; p\ 0.0001], but there was no statisti-
cally significant effect caused by interactions between time
and drugs treatment [F(30.264) = 1.36; p = 0.1093]. The
post hoc Bonferroni’s test confirmed that an acute injection
of MK-801 at the dose of 0.3 mg/kg significantly increased
locomotor activity of mice between 40 and 200 min of
experiment in comparison to the vehicle/vehicle-treated
mice (for 40 min of experiments p\ 0.05, for 60–140 min
p\ 0.001, for 160–200 min p\ 0.01). Moreover, this
hyperactivity provoked by MK-801 (0.3 mg/kg) was
attenuated by AM 251 (0.5 mg/kg) between 80 and
200 min of experiment (for 80–180 min of experiment
p\ 0.01, for 200 min p\ 0.001 vs. vehicle/MK-801
(0.3 mg/kg)-treated mice) (Fig. 6Ab).
Additionally, two-way ANOVA analyses revealed that
there was statistically significant effect caused by time
[F(10.264) = 30.66; p\ 0.0001], and drugs (MK-801
(0.6 mg/kg) and/or AM 251 (0.5 mg/kg) treatment
[F(3.264) = 52.22; p\ 0.0001], but there was no
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Fig. 5 Effect of oleamide on MK-801-induced hyperactivity in mice.
Non-effective dose of oleamide (5 mg/kg; ip) or vehicle was
administered 15 min prior to vehicle or effective (0.3 mg/kg; ip)
(A) and (0.6 mg/kg; ip) (B) MK-801 injection. After the last injection,
the mice were then tested in actimeters; n = 8–12; the mean ± SEM;
*p\ 0.05; **p\ 0.01; ***p\ 0.001 vs. vehicle/vehicle-treated
group; Bonferroni’s test
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statistically significant effect caused by interactions
between time and drugs treatment [F(30.264) = 1.49;
p = 0.0549]. The post hoc Bonferroni’s test confirmed that
an acute injection of MK-801 at the dose of 0.6 mg/kg
significantly increased locomotor activity of mice between
80 and 200 min of experiment in comparison to the vehi-
cle/vehicle-treated mice (for 80 min of experiments
p\ 0.05, for 100 min p\ 0.01, for 120–200 min
p\ 0.001). Moreover, this hyperactivity provoked by MK-
801 (0.6 g/kg) was attenuated by AM 251 (0.5 mg/kg)
between 80 and 200 min of experiment (for 80 min of
experiment p\ 0.05; for 100 min p\ 0.01, for
120–180 min p\ 0.001, for 200 min p\ 0.01) vs. vehi-
cle/MK-801 (0.6 mg/kg)-treated mice) (Fig. 6Bb).
Discussion
The correlation between cannabis and psychosis-like
effects has been a matter of debate for a long time. Several
lines of experimental and clinical evidence point out at a
close relationship between endocannabinoid system and
schizophrenia (Kucerova et al. 2014). As we mentioned in
Introduction section, CB1 receptor agonists induced
memory-related disturbances (Ferrari et al. 1999; Kruk-
Slomka and Biala 2016; Kruk-Slomka et al. 2015a; Pam-
plona and Takahashi 2006), whereas antagonists of this
type of receptors facilitated memory and learning processes
in rodents evaluated in many memory tasks (Kruk-Slomka
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Fig. 6 Effect of AM 251 on MK-801-induced hyperactivity in mice.
Non-effective dose of AM 251 (0.25 mg/kg; ip) or vehicle was
administered 15 min prior to vehicle or effective: (0.3 mg/kg; ip)
(Aa) and (0.6 mg/kg; ip) (Ba) MK-801 injection. Similarly, non-
effective dose of AM 251 (0.5 mg/kg; ip) or vehicle were adminis-
tered 15 min prior to vehicle or effective: (0.3 mg/kg; ip) (Ab) and
(0.6 mg/kg; ip) (Bb) MK-801 injection. After the last injection, the
mice were then tested in actimeters; n = 8–12; the mean ± SEM;
*p\ 0.05; **p\ 0.01; ***p\ 0.001 vs. vehicle/vehicle-treated
group; ^p\ 0.05; ^^p\ 0.01; ^^^p\ 0.001 vs. vehicle/MK-
801(0.3 mg/kg)-treated mice; #p\ 0.05; ##p\ 0.01; ###p\ 0.001
vs. vehicle/MK-801(0.6 mg/kg)-treated mice Bonferroni’s test
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Takahashi et al. 2005; Terranova et al. 1996). The
involvement of the CB1 receptors in psychotic-like effects
in animal models of schizophrenia has been also reported.
CB1 receptor agonists were able to induce effects typical
for schizophrenia; in turn, CB1 receptor antagonists had
antipsychotic properties observed in rodents (Barzegar
et al. 2015; Kucerova et al. 2014; Levin et al. 2012; Roser
and Haussleiter 2012). For example, behavioral studies
have demonstrated that an acute administration of D9-te-
trahydrocannabinol (D9-THC), the major psychoactive
component of cannabis, and a CB1 receptor agonist
impaired acquisition of memory evaluated in various
models of memory in rodents, e.g., the object recognition
task or water maze test (Da and Takahashi 2002; Lichtman
et al. 1995). On the other hand, an acute administration of
the CB1 antagonist, e.g., rimonabant improved memory
processes in the spatial memory test (Robinson et al. 2010).
Our previous studies have also confirmed that an acute
injection of oleamide, a CB1 receptor agonist, impaired the
short-term as well as long-term acquisition, consolidation,
and/or retrieval of memory and learning in the IA task. In
turn, an acute injection of AM 251, a CB1 receptor
antagonist, improved all short-term or long-term memory
stages mentioned above. Additionally, this memory
impairment induced by oleamide was reversed by AM 251
in mice during the IA test, confirming the influence of CB1
receptors (Kruk-Slomka and Biala 2016).
Based on the data cited above, the aim of the present
research was to evaluate the involvement of the endo-
cannabinoid system, through CB1 receptors, in the symp-
toms typical for schizophrenia in mice, provoked by an
acute injection of NMDA receptor antagonist, MK-801, as
an animal model of schizophrenia.
Previously, many of biochemical, molecular, and phar-
macological studies have demonstrated the functional
interactions between CB1 and NMDA receptors (Rodrı´-
guez-Mun˜oz et al. 2012; Sa´nchez-Bla´zquez et al. 2014).
For example, MK-801 at the dose of 0.1 mg/kg attenuated
the analgesic but not the hypothermic responses to D9-
THC. Indeed, pretreatment with MK-801 strongly reduced
the capacity of cannabinoids to produce analgesia (Palazzo
et al. 2001). What is more, Barzegar et al. (2015) have
shown that AM 251 prevented the somewhat inhibitory
effects of MK-801 on acquisition and retrieval in the PA
test. However, the close interactions between CB1 and
NMDA receptors in the context of schizophrenia-associ-
ated behavior have been evaluated in our presented studies
for the first time.
Our results are conformable with the psychosis-like
effects of MK-801 in animals, observed previously.
Chadman et al. (2006) revealed that the systemic admin-
istration of MK-801 (0.1 mg/kg) impaired memory and
learning processes in rats during phase of retrieval.
However, this low dose of MK-801 was not enough to
decrease memory acquisition (Ceretta et al. 2008). Simi-
larly to these cited data, our studies confirmed that an acute
injection of MK-801 (0.1–0.6 mg/kg) was able to impair
variety stages (acquisition, consolidation and retrieval) of
short- or/and long memory, as well as was able to induce
hyperactivity in mice.
Finally, in the presented studies, we have indicated that
an acute injection of CB1 receptor agonist, oleamide
(5–20 mg/kg), had no influence on the short- and long-term
memory deficits as well as on the hyperlocomotion in mice,
provoked by MK-801. The lack of effects of oleamide on
the memory impairment or hyperactivity provoked by MK-
801 obtained in our experiments may be connected with the
fact that oleamide has not been tested yet in details using
animal models. Thus, the mechanisms of activity of olea-
mide remain unknown and are still an area of current
research. However, due to the fact that oleamide is struc-
turally related to the endogenous cannabinoid, anandamide,
it seems to be able to activate the CB1 receptors as a full
agonist, e.g., the memory impairment observed in the IA
task (Kruk-Slomka and Biala 2016). However, any effects
induced by oleamide may be associated with the interaction
not only with these receptors but also with multiple other
neurotransmitter systems and receptors. Thus, more
detailed knowledge of this CB compound deserves further
investigation.
What is of interest, we have also indicated that an
amnestic effects or hyperlocomotion induced by MK-801
was attenuated by an acute administration of AM 251 (0.25
and 0.5 mg/kg), a CB1 receptor antagonist.
This strict relationship between endocannabinoid system
and schizophrenia-associated effects is connected with
many factors, neurotransmitters and receptors. It has been
known that endocannabinoid system has a strong impact on
the function of many neurotransmitter systems, including
those that are involved in the pathophysiology of
schizophrenia, e.g., the glutamatergic system. Literature
data have shown that endocannabinoid system may have
influence especially on the action of NMDA receptor
ligands, connecting strictly with psychosis or other
schizophrenia-related behavior (Javitt 2007).
It has been revealed that cannabinoids use reduced
glutamatergic synaptic transmission in several brain
regions involved in the regulation of many memory-related
functions (Auclair et al. 2000; Azad et al. 2003; Fujiwara
and Egashira 2004; Misner and Sullivan 1999; Robbe et al.
2001). For example, it has been shown that CB1 receptor
knockout mice exhibit enhanced LTP of excitatory
synaptic transmission (Bohme et al. 2000). What is more,
CB1 activation, by the administration of synthetic CB1
receptor agonists, reduced LTP and inhibited release of Glu
in the hippocampus (Sullivan 2000). These effects are
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strongly related to NMDA receptors function, which have
been implicated in learning and memory processes (Sa´n-
chez-Bla´zquez et al. 2014).
Several studies have also indicated that cannabinoids
have influence on the glutamatergic NMDA-related
receptors function through various mechanisms, such as the
presynaptic reduction of Glu release into the synaptic cleft
(Li et al. 2011) or the inhibition of postsynaptic CB1
receptors, the signaling pathways of which may interfere
with those of NMDA receptors (Hampson et al. 2011; Liu
et al. 2009; Sa´nchez-Bla´zquez et al. 2014). It has been
described that the blockade of CB1 receptors by CB1
receptor antagonist, AM 251, produced significant increase
in extracellular Glu (Xi et al. 2006). Consistent with this
report, the blockade of LTP by CB1 receptor agonists
results from a decrease in the probability of Glu release
through presynaptic receptors (Hoffman et al. 2007; Misner
and Sullivan 1999).
However, it should be noted that other interactions that
may occur between the endocannabinoid and glutamatergic
systems could be connected with a different mechanism in
which the CB1 receptors directly interact with the NMDA
receptors to diminish their activity or cannabinoids may
reduce Glu release via some other mechanism, not related
with CB1 receptors (Sa´nchez-Bla´zquez et al. 2014).
In summary, series of biochemical, molecular, pharma-
cological studies including our presented results have
demonstrated functional interactions between the endo-
cannabinoid and glutamatergic systems (Barzegar et al.
2015; Rodrı´guez-Mun˜oz et al. 2012; Sanchez-Blazquez
et al. 2014). Naturally, the data including those presented
in the present manuscript can suggest that CB1 receptor
antagonists may have therapeutic properties in
schizophrenia or other psychiatric disorders. However,
further work is necessary to explain the pharmacological
mechanisms on the behavioral level that underlie specific
psychosis-related effects induced by CB1 receptor ligands,
as well as the mechanism underlying the interactions
between CB1 and NMDA receptors.
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